All companies
Visit website
Neurocarrus
OperatingNeurocarrus Inc
Non-opioid drug treats pain without risk of addiction
Valuation cap ⓘ
$11.3M
As of Apr 2025 · from NEUROCARRUS Future Equity SAFE 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$0
Across 2 rounds since 2018
Latest share price
$1.00
NEUROCARRUS Future Equity SAFE 2 offering price
Financials
FY2016–FY2025 · from SEC filings · hover any figure for its source$0
−$29K
2017
$0
−$139K
2018
$0
−$139K
2019
$0
−$181K
2020
$194K
$6K
2022
$0
−$35K
2023
$0
$105K
2024
$2.3M
$1.4M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 1 earlier year is in the table below.
Metric
FY2016
FY2017
FY2018
FY2019
FY2020
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$0
$194,284
$0
$0
$2,314,747
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
$0
$0
Gross margin
—
—
—
—
—
100%
—
—
100%
Net income
$0
-$28,875
-$139,365
-$139,365
-$180,671
$6,171
-$35,187
$104,758
$1,418,770
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$25,322
Balance sheet
Cash
$0
$25,593
$17,287
$17,287
$163,103
$51,814
$52,150
$134,850
$1,620,657
Accounts receivable
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total assets
$0
$25,593
$91,037
$91,037
$236,853
$98,814
$166,911
$251,118
$1,644,429
Short-term debt
$0
$4,358
$4,640
$4,640
$4,513
$6,637
$27,692
$27,710
$50,277
Long-term debt
$0
$0
$100,000
$100,000
$100,000
$100,000
$82,229
$61,458
$100,000
Total liabilities
$0
$4,358
$104,640
$104,640
$104,513
$106,637
$109,921
$89,168
$150,277
Other
Headcount
—
2
—
1
1
—
3
3
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$7.5M
Valuation cap
$11.3M
Valuation cap
Reg CF Offering (2018)
NEUROCARRUS Future Equity SAFE 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised — / $618KValuation cap $11.3M
Raised $0 / $1.1MValuation cap $7.5M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGARSource: ManualCIK 0001757069Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.